필라델피아, 2025년 7월 21일 -- 미나리스 어드밴스트 테라피스(Minaris Advanced Therapies)가 오를라 클로크 박사(Dr. Orla Cloak)를 신임 최고경영자(CEO)로 임명했다고 발표했다. 클로크 박사는 제약 및 생명과학 업계에서 20년 이상 상업 분야 리더십 경험을 쌓은 경영 전문가로, 혁신, 운영 우수성, 지속 가능한 비즈니스 성장, 전략적 리더십 분야에서 입증된 실적을 보유하고 있다. 미나리스 어드밴스트 테라피스 합류 전에는 론자(Lonza)에서 17년간 다양한 리더십 직책을 역임했으며, 가장 최근에는 론자 바이오사이언스(Lonza Bioscience) 사업부 수석 부사장 겸 책임자를 역임했다. 클로크 박사는 유니버시티 칼리지 더블린(UCD)에서 이학 학사 학위를, 얼스터대학교에서 미생물학 박사 학위를 취득했다. 이언 베어드(Iain Baird) 미나리스 어드밴스드 테라피스 이사회 의장은 "이사회는 클로크 박사의 합류를 진심으로 환영한다"며 "클로크 박사의 리더십은 고객이 혁신적인 치료법을 성공적으로 상용화할 수 있도록 지원한다는 당사의 사명을 실현하는 데
TAIPEI, July 21, 2025 -- Cenra Healthcare, the sales and marketing arm of Cenra Inc. (TWSE: 3716), today announced the deepening of its long-standing collaboration with the global pharmaceutical company Dr. Reddy's Laboratories (Taiwan) Ltd (Dr. Reddy's). Since the partnership began in 2020, the two companies have worked closely to introduce a diverse range of high-quality generic drugs and innovative formulations to patients in Taiwan, with a shared commitment to broadening access to affordable and clinically valuable treatments. "We are proud to strengthen our collaborat
SHANGHAI, July 21, 2025 -- CPHI & PMEC China 2025 concluded in June with a record-breaking 109,056 attendees, underscoring strong demand within China's thriving pharma industry. Building on this success, CPHI & PMEC Shenzhen 2025 will take place from 1–3 September 2025 at Shenzhen Convention & Exhibition Center (SZCEC), addressing the growing demand for access to South China's key pharma markets. As a key gateway to the Guangdong-Hong Kong-Macau Greater Bay Area, Shenzhen is positioned to drive pharma innovation. The region's health industry GDP is projected
[ 메디채널 김갑성 기자 ] Strategic partnership to deliver transcriptomics-powered, organoid-based preclinical testing for high-impact drug discovery SEOUL, South Korea, July 21, 2025 -- CorestemChemon, a leading GLP-certified preclinical CRO based in South Korea, has entered into a strategic partnership with ATG Lifetech, a biotechnology company specializing in transcriptome analytics and organoid-based modeling. This collaboration aims to deliver next-generation, precision-driven non-clinical solutions to pharmaceutical companies and biotech ventures across the U.S., Europe, and Asia.
AUSTIN, Texas, July 21, 2025 -- Electrophysiologists at the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center recently became the first in the nation to implant an FDA-approved novel leadless system that provides cardiac resynchronization therapy to patients with heart failure. Cardiac resynchronization therapy improves the timing of the heart's contractions, helping to restore the normal rhythm of the heartbeat. The first procedure was recently performed by Robert Canby, M.D., cardiac electrophysiologist at TCAI. "This technology marks a significant advancem
오스틴, 텍사스, 2025년 7월 21일 -- 세인트 데이비드 메디컬 센터(St. David's Medical Center) 산하 텍사스 심장부정맥연구소(Texas Cardiac Arrhythmia Institute, TCAI)의 심장 전기생리학 전문의들이 심장 재동기화 치료를 제공하는 FDA 승인 신기술 무선 시스템을 미국 최초로 심부전 환자에게 이식하는 데 성공했다. 심장 재동기화 치료는 심장 수축 타이밍을 개선해 심장 박동을 정상 리듬으로 회복시키는 방법이다. 이번 첫 시술은 TCAI의 심장 전기생리학 전문의 로버트 캔비 박사(Robert Canby, M.D.)가 집도했다. TCAI의 심장 전기생리학자이자 의학총책임자인 안드레아 나탈레(Andrea Natale) 박사(F.H.R.S., F.A.C.C., F.E.S.C.)는 "이 기술은 이전까지 심장 재동기화 치료 선택지가 거의 없었던 환자들을 위한 치료 방식에 중대한 진전을 가져왔다"며, "텍사스 심장부정맥 연구소는 전 세계 환자들에게 가장 진보된 근거 기반 치료를 제공하는 데 전념하고 있으며, 캔비 박사의 리더십 덕분에 그 약속을 성공적으로 이행했다"라
BEIJING, July 18, 2025 -- This is a report from China.org.cn: At the 3rd China International Supply Chain Expo (CISCE), Canadian host Simon embarked on an immersive exploration of the advanced manufacturing zone—highlighting how global supply chains are accelerating the future of aviation, drones, and intelligent manufacturing. At the PwC booth, Simon encountered the VERTAXI eVTOL (electric vertical take-off and landing aircraft), a new-generation passenger drone designed for urban air mobility. Capable of autonomous flight and rooftop takeoff, the aircraft re
BEIJING, July 18, 2025 -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in Internet healthcare solutions, signed a Memorandum of Understanding with Novo Nordisk, a leading global healthcare company, at the 3rd China International Supply Chain Expo in Beijing. Leveraging its AI application services, innovative treatment solutions, and convenient pharmaceutical services, Fangzhou will collaborate with Novo Nordisk on managing serious chronic diseases, such as diabetes and obesity. Fangzhou's founder, chairman, and CEO Dr. Xie F
SHANGHAI, July 18, 2025 -- Jointly organized by the China Chamber of Commerce for Import & Export of Medicines & Health Products and Sinoexpo Informa Markets, the "Healthplex Expo 2025, Natural & Nutraceutical Products China 2025" (HNC 2025) was successfully held from June 24 to 26 at the National Exhibition and Convention Center (Shanghai). The HNC 2025 once again achieved a historic breakthrough in scale, winning high praise from all participants. Held concurrently with Hi & Fi Asia-China, ProPak China & FoodPack China, and Starch Expo, the HNC built a business
XIAMEN, China, July 18, 2025 -- Brain-Computer Interface (BCI) technology is redefining human-machine interaction by establishing direct communication between the brain and external devices. This transformative innovation is driving profound societal impact across industries: revolutionizing neurological disease treatment (e.g., epilepsy, Parkinson's, and depression), enhancing educational outcomes through improved focus, and enabling seamless industrial human-robot collaboration. With aging populations and rising neurological disorders worldwide, BCI's healthcare applications are experiencin